Biocon Limited

Report azionario NSEI:BIOCON

Capitalizzazione di mercato: ₹697.3b

Biocon Crescita futura

Criteri Future verificati 4/6

Biocon prevede che gli utili e i ricavi cresceranno rispettivamente di 47.6% e 13.1% all'anno. Si prevede che l'EPS crescerà di 44.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 5.7% in 3 anni.

Informazioni chiave

47.6%

Tasso di crescita degli utili

44.49%

Tasso di crescita dell'EPS

Biotechs crescita degli utili35.4%
Tasso di crescita dei ricavi13.1%
Rendimento futuro del capitale proprio5.68%
Copertura analitica

Good

Ultimo aggiornamento21 May 2026

Aggiornamenti recenti sulla crescita futura

Articolo di analisi • Aug 10

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...
Articolo di analisi • Jun 19

Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...

Recent updates

Articolo di analisi • 22h

Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture

The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...
Aggiornamento della narrazione • May 03

BIOCON: Leadership Changes And Biosimilars Expansion Will Support Future Upside

Biocon's analyst price target has been trimmed slightly to about ₹416 from roughly ₹421 as analysts factor in a marginally higher discount rate, slightly softer revenue growth and profit margin assumptions, partly balanced by a modestly higher future P/E multiple. Analyst Commentary Recent Street research around comparable life sciences names points to a cautious tone on execution risk, revenue trajectory and the willingness of the market to pay up for growth after guidance disappointments.
Aggiornamento della narrazione • Apr 19

BIOCON: Higher Profitability Assumptions Will Support U.S. Biosimilars And GLP-1 Entry

Narrative Update on Biocon Analysts have adjusted their price target on Biocon to ₹544, up from ₹465. This reflects updated assumptions around a higher fair value estimate, revised profit margin expectations, and a slightly different discount rate and forward P/E framework.
Aggiornamento della narrazione • Apr 05

BIOCON: Leadership Refresh And Biosimilars Integration Will Support Future Upside

Analysts have trimmed Biocon's fair value estimate slightly to ₹420.74 from ₹421.60, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts are treating the trimmed fair value estimate as a fine tuning of expectations rather than a major reset, with views split between what could support upside and what might cap near term returns.
Aggiornamento della narrazione • Mar 21

BIOCON: Limited P/E Expansion Will Constrain Returns Despite New Metabolic Drug Approvals

Analysts have trimmed their Biocon price target slightly to about ₹295.70 from roughly ₹297.40, reflecting a modest recalibration of fair value, discount rate and long term assumptions for revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts trimming Biocon's fair value signal a more careful stance on what they are willing to pay for the shares today, given reassessed views on growth, profitability and valuation multiples.
Aggiornamento della narrazione • Mar 07

BIOCON: Limited Multiple Expansion Will Constrain Returns Despite New GLP 1 Approvals

Narrative update Analysts have trimmed their Biocon price target slightly to about ₹297 from roughly ₹298, reflecting updated assumptions on discount rate, revenue growth, profit margins and future P/E multiples after recent sector research signalled a more cautious stance on multiple expansion. Analyst Commentary Bearish analysts looking at global life sciences peers have trimmed price targets after recent earnings misses and cautious forward commentary, and those moves are informing how some investors think about Biocon's risk and valuation setup.
Aggiornamento della narrazione • Feb 21

BIOCON: Execution And Multiple Compression Risks Will Restrain Future Share Returns

Analysts have inched up their Biocon fair value estimate to about ₹298 per share from roughly ₹295, reflecting slightly lower discount rate assumptions, modestly softer revenue growth expectations, a somewhat stronger profit margin outlook, and a marginally reduced future P/E multiple. Analyst Commentary While the fair value adjustment for Biocon is modest, some bearish analysts are still flagging risks that could cap upside in the near term.
Aggiornamento della narrazione • Feb 07

BIOCON: Equity Dilution And Biosimilars Review Will Pressure Future Returns

Analysts have slightly reduced their Biocon fair value estimate to ₹295.12 from ₹296.78, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News Biocon completed a follow on equity offering of equity shares worth ₹41.5b, issuing 112,664,585 common shares at ₹368.35 each under a Regulation S structure with a subsequent direct listing (company filing).
Aggiornamento della narrazione • Jan 23

BIOCON: Biosimilars Reorganisation And GLP 1 Expansion Will Drive Future Upside

Analysts have nudged their fair value estimate for Biocon higher from ₹412.05 to ₹421.60, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Biocon completed a follow on equity offering of ₹41.5b, issuing 112,664,585 equity shares at ₹368.35 per share under Regulation S, followed by a subsequent direct listing (Key Developments).
Aggiornamento della narrazione • Jan 09

BIOCON: Planned Capital Raise Will Likely Weigh On Future Shareholder Returns

Analysts have lifted their price target on Biocon from ₹290.00 to about ₹296.78, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E inputs in their models. What's in the News Shareholders approved amendments to Biocon's Articles of Association at the AGM held on December 31, 2025, signaling changes to the company's governing documents (Key Developments).
Aggiornamento della narrazione • Dec 26

BIOCON: Future Equity Issuance Will Likely Pressure Shareholder Returns

Analysts have maintained their fair value estimate for Biocon at ₹290.00 per share, with only minor model adjustments to discount rate, revenue growth, and profit margin assumptions. These changes have resulted in no alteration to their overall price target, as they continue to view the company’s long term earnings profile as broadly intact.
Articolo di analisi • Dec 25

Calculating The Fair Value Of Biocon Limited (NSE:BIOCON)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Biocon fair value estimate is ₹364 With ₹398 share price...
Aggiornamento della narrazione • Dec 12

BIOCON: Future Share Dilution Risk Will Likely Pressure Returns

Analysts have raised their price target on Biocon from ₹277.50 to ₹290.00, reflecting higher anticipated revenue growth, improved profit margins, and a modestly re-rated future P E multiple despite a slightly higher discount rate. What's in the News Biocon is exploring strategic options for its biosimilars arm Biocon Biologics Limited, including a potential merger with the parent company in place of an IPO, with Morgan Stanley advising on value creation alternatives (Key Developments).
Articolo di analisi • Dec 07

Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel

You may think that with a price-to-sales (or "P/S") ratio of 3.2x Biocon Limited ( NSE:BIOCON ) is a stock worth...
Aggiornamento della narrazione • Nov 27

BIOCON: Global Expansion And Business Restructuring Are Expected To Balance Opportunities And Risks

Analysts have raised their price target for Biocon from ₹395.65 to ₹412.05. This change reflects updated expectations around key valuation inputs and profitability metrics.
Articolo di analisi • Nov 19

Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)

The market rallied behind Biocon Limited's ( NSE:BIOCON ) stock, leading do a rise in the share price after its recent...
Aggiornamento della narrazione • Nov 13

BIOCON: Revenue Outlook And Global Expansion Likely To Support Steady Performance

Analysts have raised Biocon's fair value price target from ₹376.70 to ₹395.65, citing improved revenue growth projections and profit margins as key drivers for the upgrade. What's in the News Biocon announced the public funding of YESAFILI (aflibercept), a biosimilar to EYLEA, on the Ontario Drug Benefit Formulary in Canada for retinal disease treatment.
Aggiornamento della narrazione • Oct 05

Biosimilars Demand Will Unlock Global Market Opportunities

Analysts have lowered Biocon's price target slightly from ₹380.11 to ₹376.70, citing marginal adjustments in the discount rate and projected earnings metrics. Analyst Commentary Market watchers have weighed in on Biocon's valuation following the recent adjustment to its price target.
Articolo di analisi • Sep 22

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price

Key Insights The projected fair value for Biocon is ₹577 based on 2 Stage Free Cash Flow to Equity Biocon's ₹369 share...
Articolo di analisi • Aug 10

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...
Articolo di analisi • Aug 04

Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now

Biocon Limited's ( NSE:BIOCON ) price-to-earnings (or "P/E") ratio of 50.5x might make it look like a strong sell right...
Articolo di analisi • Jun 19

Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...
Articolo di analisi • Jun 18

Biocon (NSE:BIOCON) Will Pay A Dividend Of ₹0.50

The board of Biocon Limited ( NSE:BIOCON ) has announced that it will pay a dividend on the 5th of September, with...
User avatar
Nuova narrazione • Dec 12

Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability

Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.

Previsioni di crescita degli utili e dei ricavi

NSEI:BIOCON - Stime future degli analisti e dati finanziari passati (INR Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
3/31/2029249,13321,93924,82747,1416
3/31/2028228,62819,94527,42741,52218
3/31/2027200,53413,69222,77538,09618
3/31/2026169,2703,85682319,940N/A
12/31/2025168,2746,042N/AN/AN/A
9/30/2025164,7584,85517,97341,592N/A
6/30/2025157,7073,850N/AN/AN/A
3/31/2025152,61710,13317,17940,612N/A
12/31/2024147,6188,043N/AN/AN/A
9/30/2024148,94114,39221,04540,368N/A
6/30/2024147,66015,808N/AN/AN/A
3/31/2024147,55710,22510,22329,539N/A
12/31/2023146,12512,002N/AN/AN/A
9/30/2023135,9994,984-6,24111,717N/A
6/30/2023124,5734,197N/AN/AN/A
3/31/2023111,7424,6271,26218,525N/A
12/31/202298,0913,881N/AN/AN/A
9/30/202290,4226,170-6,83611,543N/A
6/30/202285,6297,084N/AN/AN/A
3/31/202281,8406,484-7,48211,766N/A
12/31/202175,8006,727N/AN/AN/A
9/30/202172,6326,542-6,36612,763N/A
6/30/202171,7266,852N/AN/AN/A
3/31/202171,4317,405-5,86611,597N/A
12/31/202068,9135,996N/AN/AN/A
9/30/202067,5716,362-6,57610,484N/A
6/30/202065,7966,870N/AN/AN/A
3/31/202063,0057,771-5,53412,831N/A
12/31/201963,1508,385N/AN/AN/A
9/30/201961,0778,529N/A14,573N/A
6/30/201958,5659,919N/AN/AN/A
3/31/201955,1449,053N/A11,546N/A
12/31/201851,5518,220N/AN/AN/A
9/30/201846,7226,967N/AN/AN/A
6/30/201843,1984,108N/AN/AN/A
3/31/201841,2343,724N/A6,621N/A
12/31/201738,7923,695N/AN/AN/A
9/30/201738,5894,489N/AN/AN/A
6/30/201738,3615,268N/AN/AN/A
3/31/201738,9116,121N/A6,400N/A
12/31/201640,48711,633N/AN/AN/A
9/30/201638,11010,961N/AN/AN/A
6/30/201636,5399,388N/AN/AN/A
3/31/201633,4745,504N/A3,706N/A
12/31/201532,9977,367N/AN/AN/A
9/30/201532,3257,247N/AN/AN/A
6/30/201531,5285,207N/AN/AN/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di BIOCON ( 47.6% all'anno) è superiore al tasso di risparmio ( 6.9% ).

Guadagni vs Mercato: Si prevede che gli utili di BIOCON ( 47.6% all'anno) cresceranno più rapidamente del mercato Indian ( 16.4% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di BIOCON cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di BIOCON ( 13.1% all'anno) crescerà più rapidamente del mercato Indian ( 10.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di BIOCON ( 13.1% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di BIOCON sarà basso tra 3 anni ( 5.7 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/21 22:19
Prezzo dell'azione a fine giornata2026/05/21 00:00
Utili2026/03/31
Utili annuali2026/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Biocon Limited è coperta da 39 analisti. 18 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Rohit Bhat360 ONE Capital Market Private Limited
Meeta ShettyAsian Markets Securities Private Limited
Harith AhamedAvendus Spark